The current financial score of Celldex Therapeutics Inc is 5.69. Its financial status is stable, and its operating efficiency is low.
The current valuation score of Celldex Therapeutics Inc is 7.90. Its current P/E ratio is -7.32, which is -23.58% below the recent high of -5.59 and -170.45% above the recent low of -19.80.
The current earnings forecast score of Celldex Therapeutics Inc is 8.53. The average price target is 63.07, with a high of 100.00 and a low of 28.00.
The current price momentum score of Celldex Therapeutics Inc is 3.96. Currently, the stock price is trading between the resistance level at 32.77 and the support level at 28.59, making it suitable for range-bound swing trading.
The current institutional shareholding score of Celldex Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 96.30%, representing a quarter-over-quarter decrease of 26.99%.
The current risk assessment score of Celldex Therapeutics Inc is 5.89. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.